 |
 |
||||||
[August 2004]
New Biocomposite Extends Ceramic Portion Resorption
OBI - OsteoBiologics Inc (San Antonio, TX, USA) has received 510(k) Premarket Notification from the FDA in the US to market and distribute its newest formulation of composite bone void filler device called PolyGraft(tm) TCP Bone Graft Substitute.
The porous PolyGraft TCP material is composed of a patented blend of fibres and can be fabricated into products such as granules, blocks, wedges and other preformed shapes and is indicated to be used to fill bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of the bony structure.
"OBI has developed another composite bone void filler in which the ceramic portion resorbs slower to enhance strength retention," stated Fred Dinger, President and CEO of OBI. "The availability of this technology platform gives OBI the opportunity to continue our rapid product line expansion and enables us to provide solutions for the body to heal itself for a broader range of unmet clinical needs."
ENDS